ADAPT-EARLYNCT06909214
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 6 more changesShow less
- Eligibility criteria expanded, about 9 words
- Enrollment increased: 30 → 35 participants
- Study completion pushed from May 2027 to Dec 2027
- Primary completion date changed from estimate of Aug 2026 to Jul 8, 2026
- Secondary endpoints: details revised at 4 of 4 entries
- Site details revised at 1 of 18 sites
- Minor Site details revised at 1 of 18 sitesv10
- Minor Study sites: 17 to 18v9
- Minor Study sites: 16 to 17v8
- Minor Study sites: 15 to 16v7
Show 5 earlier versionsHide 5 earlier versions
- Minor Study sites: 12 to 15v6
- Minor Study sites: 4 to 12v5
- Minor Study sites: 3 to 4v4
- Minor Study sites: 1 to 3v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Apr 2025 to Apr 17, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of participants who reach MSE of MG at any time within the first 16 weeks of stage 1 treatment with efgartigimod PH20 SC
Timeframe: up to 16 weeks
Secondary (4)
Changes from baseline in MG-ADL total scores over time
Changes from baseline in MG-QOL-15r total scores over time
Proportion of participants who are administered systemic corticosteroid therapy as background add-on therapy throughout the study
Incidence of adverse events, serious adverse events and adverse events leading to study drug discontinuation
Arms and interventions
Efgartigimod PH20 SCExperimental
Participants receiving efgartigimod PH20 SC
Biologicals: Efgartigimod PH20 SC
Sites
18 sites in 1 country